by Patient Derived Xenograft (PDX) models closely reflect the molecular and clinical characteristics of human tumors and is advantageous for efficiently testing therapeutic approaches. PDX models are grown from surgically resected tumor tissues directly implanted into immunodeficient mice to enable tumor growth and expansion while retaining all aspects of the original patient tumor including histology, gene expression and mutant genotype. This allows researchers to accurately predict therapeutic responses in preclinical experiments and expedite development of personalized treatment strategies.
The Global Patient Derived Xenograft Model Market is estimated to be valued at US$ 105.4 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Patient Derived Xenograft Model are Aksa Akrilik Kimya Sanayii A.S.(Aksa), Dralon, Aditya Birla Group, Jilin Chemical Fibre Company, Taekwang Industrial Co., LTD, Exlan Japan Co., Ltd., Kaneka Corporation, Indian Acrylics Limited, Pasupati Acrylon Ltd., and Vardhman Acrylics Ltd. These players are focusing on portfolio expansion and acquisitions to increase market share.
Growing Patient Derived Xenograft Model market Demand for personalized medicine is fueling adoption of PDX models for developing targeted therapies. Researchers are increasingly leveraging these models for biomarker validation and drug screening to accelerate clinical trials.
Increasing investments by pharmaceutical companies in oncology drug development is driving global expansion of the patient derived xenograft market. Regional government initiatives to promote R&D activities are also propelling market growth.
Market key trends
Adoption of new Patient Derived Xenograft Model Market such as microfluidics, organ-chip models and CRISPR gene editing in PDX models is a key trend. These technologies enable 3D tumor microenvironments for better predictive power. Increased genomic and molecular characterization of PDX models is also gaining traction for guiding biomarker-driven clinical trials. Additionally, development of implantable PDX models that can be monitored non-invasively for drug response is expected to revolutionize preclinical testing over the forecast period.
Porter’s Analysis
Threat of new entrants: New entrants face high entry barriers due to the high costs associated with R&D and manufacturing.
Bargaining power of buyers: Buyers have moderate bargaining power due to the presence of substitutes and differentiated products offered by existing players.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to the availability of substitute raw materials.
Threat of new substitutes: Threat of new substitutes is moderate as research is ongoing to develop alternatives.
Competitive rivalry: The Patient Derived Xenograft Model Market Regional Analysisis is highly competitive due to the presence of global established players.
Geographical Regions
North America accounts for the largest market share currently due to presence of major players and availability of advanced healthcare facilities for research. Asia Pacific is expected to be the fastest growing region due to increasing awareness, improving healthcare infrastructure and rising research spending in countries like China and India.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
